Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Cardiology Reports
Erschienen in: Current Cardiology Reports 5/2017

01.05.2017 | Nuclear Cardiology (V Dilsizian, Section Editor)

Cardiac Applications of PET-MR

verfasst von: Peter J. Bergquist, Michael S. Chung, Anja Jones, Mark A. Ahlman, Charles S. White, Jean Jeudy

Erschienen in: Current Cardiology Reports | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The purpose of this study was to provide an overview of the clinical applications of PET-MR in the setting of cardiac imaging with emphasis on specific scenarios where both techniques together provided added information.

Recent Findings

Synergy of cardiac PET and MR fusion may hold similar promise eliminating ionizing radiation and improving tissue contrast. Future development of new hybrid scanners, use of new imaging tracers, and clinical applications are significant factors which will influence its use.

Summary

Both positron emission tomography (PET) and cardiac magnetic resonance imaging (CMR) provide important anatomic and physiologic information with regard to the heart. Being able to combine the data from these two examinations in a hybrid technique allows for a more complete evaluation of cardiac pathology. While hybrid PET-CT has already established the utility of a combined imaging approach, the use of CMR in lieu of CT allows for elimination of ionizing radiation and for improved tissue contrast.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zaidi H, Montandon M-L, Alavi A. The clinical role of fusion imaging using PET, CT, and MR imaging. Magn Reson Imaging Clin N Am. 2010-2;18:133–49.CrossRefPubMed
2.
Ripa RS, Knudsen A, Hag AMF, Lebech A-M, Loft A, Keller SH, Hansen AE, von Benzon E, Højgaard L, Kjær A. Feasibility of simultaneous PET/MR of the carotid artery: first clinical experience and comparison to PET/CT. Am J Nucl Med Mol Imaging. 2013;3:361–71.PubMedPubMedCentral
3.
Li X, Heber D, Rausch I, et al. Quantitative assessment of atherosclerotic plaques on (18)F-FDG PET/MRI: comparison with a PET/CT hybrid system. Eur J Nucl Med Mol Imaging. 2016;43:1503–12.CrossRefPubMedPubMedCentral
4.
Hyafil F, Schindler A, Sepp D, et al. High-risk plaque features can be detected in non-stenotic carotid plaques of patients with ischaemic stroke classified as cryptogenic using combined (18)F-FDG PET/MR imaging. Eur J Nucl Med Mol Imaging. 2016;43:270–9.CrossRefPubMed
5.
Durrani AK, Lau JM, Laforest R, Zheng J, Priatna A, Gropler RJ, Woodard PK (2015) 13N–ammonia PET/MR Myocardial Stress Perfusion Imaging Early Experience. Radiological Society of North America, 2015 Scientific Assembly and Annual Meeting; 2015 Dec 3; Chicago, IL. Available from: http://​archive.​rsna.​org/​2015/​15012463.​html.
6.
Lau JMC, Laforest R, Priatna A, Sharma S, Zheng J, Gropler RJ, Woodard PK. Demonstration of intermittent ischemia and stunning in hibernating myocardium. J Nucl Cardiol. 2013;20:908–12.CrossRefPubMedPubMedCentral
7.
Schindler TH. Positron-emitting myocardial blood flow tracers and clinical potential. Prog Cardiovasc Dis. 2015;57:588–606.CrossRefPubMed
8.
Schiebler ML, Nagle SK, François CJ, Repplinger MD, Hamedani AG, Vigen KK, Yarlagadda R, Grist TM, Reeder SB. Effectiveness of MR angiography for the primary diagnosis of acute pulmonary embolism: clinical outcomes at 3 months and 1 year. J Magn Reson Imaging. 2013;38:914–25.CrossRefPubMedPubMedCentral
9.
Xie Y, Pang J, Kim YJ, et al. Coronary atherosclerosis T1-weighed characterization with integrated anatomical reference (CATCH). J Cardiovasc Magn Reson. 2016;18:1–3.CrossRef
10.
11.
•• Turkbey EB, Nacif MS, Guo M, et al. Prevalence and correlates of myocardial scar in a US cohort. JAMA. 2015;314:1945–54. Using the cohort of Multi-Ethnic Study of Atherosclerosis (MESA) study, the authors determined the prevalence of unrecognized myocardial scar in 6.2% of the study population. CrossRefPubMedPubMedCentral
12.
Flotats A, Bravo PE, Fukushima K, Chaudhry MA, Merrill J, Bengel FM. 82Rb PET myocardial perfusion imaging is superior to 99mTc-labelled agent SPECT in patients with known or suspected coronary artery disease. Eur J Nucl Med Mol Imaging. 2012;39:1233–9.CrossRefPubMed
13.
Parker MW, Iskandar A, Limone B, Perugini A, Kim H, Jones C, Calamari B, Coleman CI, Heller GV. Diagnostic accuracy of cardiac positron emission tomography versus single photon emission computed tomography for coronary artery disease: a bivariate meta-analysis. Circ Cardiovasc Imaging. 2012;5:700–7.CrossRefPubMed
14.
Klocke FJ, Baird MG, Lorell BH, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging--executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (ACC/AHA/ASNC Committee to revise the 1995 guidelines for the clinical use of cardiac radionuclide imaging). J Am Coll Cardiol. 2003;42:1318–33.CrossRefPubMed
15.
•• Rischpler C, Nekolla SG, Kunze KP, Schwaiger M. PET/MRI of the heart. Semin Nucl Med. 2015;45:234–47. An excellent review of the technical challenges and potential clinical applications of PET/MR. CrossRefPubMed
16.
Schwitter J, Nanz D, Kneifel S, Bertschinger K, Büchi M, Knüsel PR, Marincek B, Lüscher TF, von Schulthess GK. Assessment of myocardial perfusion in coronary artery disease by magnetic resonance: a comparison with positron emission tomography and coronary angiography. Circulation. 2001;103:2230–5.CrossRefPubMed
17.
Nandalur KR, Dwamena BA, Choudhri AF, Nandalur MR, Carlos RC. Diagnostic performance of stress cardiac magnetic resonance imaging in the detection of coronary artery disease: a meta-analysis. J Am Coll Cardiol. 2007;50:1343–53.CrossRefPubMed
18.
Greenwood JP, Maredia N, Younger JF, et al. Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial. Lancet. 2012;379:453–60.CrossRefPubMedPubMedCentral
19.
Morton G, Chiribiri A, Ishida M, et al. Quantification of absolute myocardial perfusion in patients with coronary artery disease: comparison between cardiovascular magnetic resonance and positron emission tomography. J Am Coll Cardiol. 2012;60:1546–55.CrossRefPubMed
20.
Tillisch J, Brunken R, Marshall R, Schwaiger M, Mandelkern M, Phelps M, Schelbert H. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med. 1986;314:884–8.CrossRefPubMed
21.
Schinkel AFL, Poldermans D, Elhendy A, Bax JJ. Assessment of myocardial viability in patients with heart failure. J Nucl Med. 2007;48:1135–46.CrossRefPubMed
22.
Dickfeld T, Tian J, Ahmad G, et al. MRI-guided ventricular tachycardia ablation: integration of late gadolinium-enhanced 3D scar in patients with implantable cardioverter-defibrillators. Circ Arrhythm Electrophysiol. 2011;4:172–84.CrossRefPubMed
23.
Cummings KW, Bhalla S, Javidan-Nejad C, Bierhals AJ, Gutierrez FR, Woodard PK. A pattern-based approach to assessment of delayed enhancement in nonischemic cardiomyopathy at MR Imaging1. Radiographics. 2009;29:89–103.CrossRefPubMed
24.
Friedrich MG, Sechtem U, Schulz-Menger J, et al. Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol. 2009;53:1475–87.CrossRefPubMedPubMedCentral
25.
Takano H, Nakagawa K, Ishio N, Daimon M, Daimon M, Kobayashi Y, Hiroshima K, Komuro I. Active myocarditis in a patient with chronic active Epstein–Barr virus infection. Int J Cardiol. 2008;130:e11–3.CrossRefPubMed
26.
von Olshausen G, Hyafil F, Langwieser N, Laugwitz K-L, Schwaiger M, Ibrahim T. Detection of acute inflammatory myocarditis in Epstein Barr virus infection using hybrid 18F-fluoro-deoxyglucose-positron emission tomography/magnetic resonance imaging. Circulation. 2014;130:925–6.CrossRef
27.
Piriou N, Sassier J, Pallardy A, Serfaty J-M, Trochu J-N. Utility of cardiac FDG-PET imaging coupled to magnetic resonance for the management of an acute myocarditis with non-informative endomyocardial biopsy. Eur Heart J Cardiovasc Imaging. 2015;16:574.CrossRefPubMed
28.
Vignaux O, Dhote R, Duboc D, Blanche P, Devaux J-Y, Weber S, Legmann P. Detection of myocardial involvement in patients with sarcoidosis applying T2-weighted, contrast-enhanced, and cine magnetic resonance imaging: initial results of a prospective study. J Comput Assist Tomogr. 2002;26:762–7.CrossRefPubMed
29.
30.
Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013;6:501–11.CrossRefPubMed
31.
32.
Blankstein R, Osborne M, Naya M, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol. 2014;63:329–36.CrossRefPubMed
33.
Youssef G, Leung E, Mylonas I, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and Metaanalysis including the Ontario experience. J Nucl Med. 2012;53:241–8.CrossRefPubMed
34.
Takeda N, Yokoyama I, Hiroi Y, Sakata M, Harada T, Nakamura F, Murakawa Y, Nagai R. Positron emission tomography predicted recovery of complete A-V nodal dysfunction in a patient with cardiac sarcoidosis. Circulation. 2002;105:1144–5.CrossRefPubMed
35.
White JA, Rajchl M, Butler J, Thompson RT, Prato FS, Wisenberg G. Active cardiac sarcoidosis: first clinical experience of simultaneous positron emission tomography-magnetic resonance imaging for the diagnosis of cardiac disease. Circulation. 2013;127:e639–41.CrossRefPubMed
36.
Rischpler C, Nekolla SG, Dregely I, Schwaiger M. Hybrid PET/MR imaging of the heart: potential, initial experiences, and future prospects. J Nucl Med. 2013;54:402–15.CrossRefPubMed
37.
O’Meara C, Menezes LJ, White SK, Wicks E, Elliott P. Inital experience of imaging cardiac sarcoidosis using hybrid PET-MR - a technologist’s case study. J Cardiovasc Magn Reson. 2013;15:T1.PubMedCentral
38.
Rubinshtein R, Glockner JF, Ommen SR, et al. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail. 2010;3:51–8.CrossRefPubMed
39.
Chan RH, Maron BJ, Olivotto I, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014;130:484–95.CrossRefPubMed
40.
Maron MS, Appelbaum E, Harrigan CJ, Buros J, Gibson CM, Hanna C, Lesser JR, Udelson JE, Manning WJ, Maron BJ. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail. 2008;1:184–91.CrossRefPubMed
41.
Kong E-J, Lee S-H, Cho I-H. Myocardial fibrosis in hypertrophic cardiomyopathy demonstrated by integrated cardiac F-18 FDG PET/MR. Nucl Med Mol Imaging. 2013;47:196–200.CrossRefPubMedPubMedCentral
42.
Aoyama R, Takano H, Kobayashi Y, Kitamura M, Asai K, Kumita S-I, Shimizu W. Evaluation of myocardial glucose metabolism in hypertrophic cardiomyopathy by 18F-Fluorodeoxyglucose positron emission tomography: impact of alcohol septal ablation therapy. J Am Coll Cardiol. 2016;67:1520.CrossRef
43.
Burke A, Jeudy J Jr, Virmani R (2007) Cardiac Tumors. In: Topol EJ, Califf RM (eds) Textbook of Cardiovascular Medicine, Third. Lippincott Williams & Wilkins, pp 710–18.
44.
• Nensa F, Tezgah E, Poeppel TD, Jensen CJ, Schelhorn J, Köhler J, Heusch P, Bruder O, Schlosser T, Nassenstein K. Integrated 18F-FDG PET/MR imaging in the assessment of cardiac masses: a pilot study. J Nucl Med. 2015;56:255–60. This article demonstrates the utility of PET-MR with the assessment of malignancy in diagnostic workup of cardiac tumors. CrossRefPubMed
Metadaten
Titel
Cardiac Applications of PET-MR
verfasst von
Peter J. Bergquist
Michael S. Chung
Anja Jones
Mark A. Ahlman
Charles S. White
Jean Jeudy
Publikationsdatum
01.05.2017
Verlag
Springer US
Erschienen in
Current Cardiology Reports / Ausgabe 5/2017
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-017-0847-9

Weitere Artikel der Ausgabe 5/2017

Current Cardiology Reports 5/2017 Zur Ausgabe

Lipid Abnormalities and Cardiovascular Prevention (G De Backer, Section Editor)

Strengths and Limitations of Using the Polypill in Cardiovascular Prevention

New Therapies for Cardiovascular Disease (KW Mahaffey, Section Editor)

Adjuvant Antithrombotic Therapy in TAVR

Lipid Abnormalities and Cardiovascular Prevention (G De Backer, Section Editor)

Genetic Architecture of Familial Hypercholesterolaemia

Pericardial Disease (AL Klein, Section Editor)

New Cardiac Imaging Algorithms to Diagnose Constrictive Pericarditis Versus Restrictive Cardiomyopathy

Nuclear Cardiology (V Dilsizian, Section Editor)

Cardiac Complications of Cancer Therapy: Pathophysiology, Identification, Prevention, Treatment, and Future Directions

Ischemic Heart Disease (D Mukherjee, Section Editor)

Genetics of Dyslipidemia and Ischemic Heart Disease

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise